Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash Flows from Operating activities:
Net (loss) income	$ (11,506)	$ 6,910
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	310	242
Reserve for inventory obsolescence	423	52
Change in fair value of preferred stock warrant and contingent shares liability	(196)	512
Non-cash interest expense	2,235	47
Stock-based compensation	2,505	366
Allowance for credit losses	(990)	109
Loss on debt extinguishment		171
Non-cash lease expense	300	167
Accretion of interest on marketable securities	(128)	(7)
Changes in operating assets and liabilities:
Accounts receivable	1,546	(16,535)
Inventory	5,221	(11,780)
Prepaid expenses and other assets	845	(1,175)
Accounts payable	(9,448)	14,815
Accrued expenses and other liabilities	(2,207)	407
Deferred revenue	250	486
Warranty liability	(153)	275
Operating lease liabilities	(273)	(149)
Net cash used in operating activities	(11,266)	(5,087)
Investing activities:
Purchase of marketable securities		(10,068)
Acquisition of fSight		55
Purchase of intangible assets		(450)
Purchase of property and equipment	(367)	(192)
Sales and maturities of marketable securities	16,003
Net cash provided (used) by investing activities	15,636	(10,655)
Financing activities:
Proceeds from Convertible Promissory Note		50,000
Repayment of from Series 2022-1 Notes		(20,833)
Payment of financing costs		(100)
Payment of deferred issuance costs related to future equity issuance		(527)
Proceeds from exercise of stock options	250	91
Net cash provided by financing activities	250	28,631
Net increase in cash and cash equivalents	4,620	12,889
Cash and cash equivalents at beginning of period	4,405	37,717
Cash and cash equivalents at end of period	9,025	50,606
Supplemental disclosure of cash flow information:
Cash paid for interest	1,250	168
Cash paid for income taxes	126
Supplemental schedule of non-cash investing and financing activities:
Deferred issuance costs related to future equity issuance in accrued expenses and accounts payable		174
Financing costs in accounts payable		257
Operating lease right of use assets obtained in exchange for operating lease liabilities	82	1,266
Property and equipment in accounts payable	32	1,026
Non-cash consideration paid for the acquisition of fSight	239	10,078
Contingent shares liability from fSight acquisition	92	1,990
Unrealized gain resulting from change in fair value of marketable securities	$ 12	$ 14